Oral Answers to Questions

Debate between Mark Durkan and Norman Lamb

Tuesday 16th April 2013 Commons Chamber

[Mark Durkan (Foyle) (SDLP)]

11. What steps the Government plan to take to ensure that patients with rare and very rare muscle-wasting conditions have access to high cost drugs when such treatments become available.

[The Minister of State, Department of Health (Norman Lamb)]

Our priority is to ensure that patients in England, including those with rare and very rare muscle-wasting conditions, have access to new and effective treatments on terms that represent value to the NHS and the taxpayer.

[Mark Durkan]

The all-party parliamentary group for muscular dystrophy, which has been conducting an inquiry, was told recently that patients who are experiencing muscle-wasting conditions, and their families, are concerned about the possibility that they will be denied access to potential treatment because of regulatory barriers, and/or on cost grounds. Will the Minister meet the all-party group to discuss measures for the removal of any such impediments?

[Norman Lamb]

I am certainly willing to meet the all-party group, but I think that significant new opportunities are emerging. For example, from this month the National Institute for Health and Clinical Excellence will be responsible for the evaluation of new drugs for the treatment of rare conditions, and I think that that is a very good thing.

Thalidomide Victims

Debate between Mark Durkan and Norman Lamb

Wednesday 5th September 2012 Westminster Hall

[Norman Lamb]

I am keen to make this a priority to try and reach a decision as quickly as we can. There are two issues: it is not only about providing certainty as soon as possible, but about how long the period of the grant would be. I recognise the argument in support of a longer period, in order to provide people with more certainty for the future. I need to look at all those matters, hear from the trust and officials, and read the reports that have come in before making my decision, but I want to make it quickly.

[Mark Durkan (Foyle) (SDLP)]

I thank the Minister for giving way and I welcome him to his post. In July, when I asked his predecessor in the Chamber about the lack of a substantive commitment when he met the national advisory council to the Thalidomide Trust, he promised that that would be looked at carefully. He said that there would be further discussions with a view to concluding in autumn. Does the Minister accept that the conclusion will need more strategy and purpose, and not just be a periodic, time-limited top-up to the pilot fund? It has to be something better than “Pilot 2”.

[Norman Lamb]

I can reveal to hon. Members that the hon. Gentleman and I talked about that on Westminster bridge as we walked in this morning. Those are exactly the issues that I want to consider. Incidentally, I should pay tribute to my predecessor Minister, who worked closely with the trust to deal with such matters properly and effectively. I know that he was absolutely committed to doing so. He said that he would make a decision in the autumn, and I stick with that.

When a former Minister of State for Health, Mike O’Brien, announced the grant, he stated that the difference that it made to individuals’ lives would be evaluated. We have received the evaluation report on the second year of the grant’s operation, as the hon. Member for Glasgow Central (Anas Sarwar) mentioned. Officials in the Department of Health and the devolved Health Departments have had the opportunity to meet the trust and discuss the evaluation report, and they are assessing how the grant is delivering against the objectives that have been set. It is important that a full, objective assessment is made of how effective the pilot has been at enabling independence, health and well-being in the way that was intended. The stories emerging appear to be very powerful. We all want to delay health deterioration and preserve independence as long as possible, and I am acutely aware, as has been mentioned, of the fulfilling lives that so many people have led despite suffering as a result of thalidomide. That is a powerful message. I will do everything that I can to reach the right decision quickly, and I am grateful to the hon. Member for Kilmarnock and Loudoun for securing the debate.

Oral Answers to Questions

Debate between Mark Durkan and Norman Lamb

Thursday 24th May 2012 Commons Chamber

[Mark Durkan (Foyle) (SDLP)]

Do the Government accept the evidence from R3 that businesses in administration find it expensive or impossible to trade because of the ransom tactics of suppliers, particularly on-suppliers. Will they address the shortcomings in the Insolvency Act 1986, which fails to provide firms with the protections they would have under chapter 11 in the United States?

[Norman Lamb]

I will look into the issue the hon. Gentleman raises and will be happy to discuss it with him.

Oral Answers to Questions

Debate between Mark Durkan and Norman Lamb

Thursday 15th March 2012 Commons Chamber

[Norman Lamb]

The adjudicator will have powers of investigation. On the question of fines, there will be a reserve power in the Bill. However, the Government take the view that the other powers, particularly the power to name and shame supermarkets, should be sufficient to have a significant effect on behaviour. If they do not have that effect, there will be the reserve power to introduce fines.

[Mark Durkan (Foyle) (SDLP)]

Will the Minister ensure that when the Bill emerges, it has the necessary legislative consent motion from the Northern Ireland Assembly, so that it can apply across the jurisdiction?

[Norman Lamb]

I will certainly look into ensuring that it does.